Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Summary

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Timeline

Start

2025-07-21

Primary completion

2029-06-30

Completion

2029-06-30

Publications

• Chan JA, Strosberg JR, Yoo C, Singh S, Huang H, Goel M, Scheffold C, Capdevila J. STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors. Future Oncol. 2026 Sep 28:1-8. doi: 10.1080/14796694.2026.2733790. Online ahead of print.

Drugs

Indications